plerixafor has been researched along with Atrophy in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Boltze, J; Campos, RMP; Conde, L; Didwischus, N; Mendez-Otero, R; Pimentel-Coelho, PM; Spiess, DA | 1 |
Englund, E; Issazadeh-Navikas, S; Kuric, E; Liu, Y; Ruscher, K; Walter, HL; Wieloch, T | 1 |
2 other study(ies) available for plerixafor and Atrophy
Article | Year |
---|---|
Subacute AMD3100 Treatment Is Not Efficient in Neonatal Hypoxic-Ischemic Rats.
Topics: Animals; Animals, Newborn; Atrophy; Benzylamines; Brain; Cognitive Dysfunction; Cyclams; Endpoint Determination; Female; Hypoxia-Ischemia, Brain; Male; Maze Learning; Pregnancy; Psychomotor Performance; Rats; Rats, Wistar; Receptors, CXCR4; Sex Characteristics; Treatment Failure | 2022 |
Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke.
Topics: Animals; Atrophy; Benzylamines; Blotting, Western; Brain; Brain Ischemia; Chemokine CXCL12; Cyclams; DNA; DNA Fragmentation; Down-Regulation; Environment; Flow Cytometry; Fluorescent Antibody Technique; Heterocyclic Compounds; Immunohistochemistry; Ischemic Attack, Transient; Male; Middle Cerebral Artery; Rats; Rats, Inbred SHR; Receptors, CXCR4; Recovery of Function; Signal Transduction; Spleen; Stroke | 2013 |